Outcome of the Meeting of Board of Directors held on Thursday, May 21, 2026.

Revenue growth above 20%Profit growth above 25%Going-concern doubtEmphasis of matterResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹1.17

prior close

₹1.22

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+4.2% vs market

Trading & Distributors peers, median of 131sector+0.0%+4.3% vs sector

On the reaction day the stock moved 4.2 pts more than Nifty Microcap 250 and 4.3 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3+0.1+4.2+0.0+4.3

Next day

+9.4+1.7+7.7+0.4+9.1

+10.3+2.4+7.9+1.1+9.1

+6.8+2.4+4.5+0.5+6.3

+1.7+1.7-0.0+0.0+1.7

+0.9+0.6+0.3-0.0+0.9

-0.9+1.9-2.8-0.6-0.2

15d

-3.4+4.9-8.3-0.7-2.8

-4.3+8.9-13.2-0.1-4.2

-8.5+7.5-16.1-4.8-3.8

-12.8+13.6-26.4-5.1-7.7

UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 131Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Genpharmasec Limited reported strong financial results for FY2026 ended March 31, 2026. Standalone revenue from operations grew significantly to Rs 13,555.56 Lakhs from Rs 3,296.07 Lakhs in FY2025, representing over 311% growth. Profit after tax stood at Rs 544.96 Lakhs versus Rs 280.04 Lakhs in the prior year, a growth of approximately 95%. The Board approved the audited standalone and consolidated financial results, with Statutory Auditors Bilimoria Mehta & Co. issuing an unmodified (clean) opinion. The company also re-appointed M/s. Abhishek M Agrawal & Co. as Internal Auditor for FY2026-27. Key notes include reclassification of equity shares from Inventories to Financial Investments (FVOCI), and acquisition of Derren Healthcare Private Limited as a subsidiary in July 2025.

Likely market impact

The company demonstrated exceptional revenue and profit growth in FY2026, which could be positive for the stock. However, the auditor flagged going concern doubts for two subsidiaries (Derren Healthcare and Clinigenome India) that have incurred losses and face liquidity challenges, adding risk for investors.